Merck KGaA (MKKGY)
Pharmaceutical Preparations · market cap $65.8B · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
- 2026-11-24 (est.)Phase 3 · Avelumabimp 9/10
- 2027-01-15 (est.)Phase 2 · Bintrafusp alfaimp 7/10
- 2027-09-30 (est.)Phase 3 · Cetrorelix acetateimp 9/10
- 2027-11-15 (est.)Phase 2 · Mirdametinibimp 7/10
| Asset | Phase | Indication |
|---|---|---|
| Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF) | Phase 2 | Infertility Implantation Failure |
| Saizen® | Phase 3 | Idiopathic Short Stature |
| GONAL-f® | Phase 3 | Infertility |
| AS900672-Enriched | Phase 2 | Infertility |
| Follitropin alfa 150 international unit (IU) | Phase 2 | Infertility |
| Pergoveris® | Phase 3 | Assisted Reproductive Techniques |
| 5Fluorouracil | Phase 3 | Metastatic Colorectal Cancer |
| Racemate Praziquantel ODT | Phase 2 | Schistosomiasis |
| Recombinant human chorionic gonadotropin (r-hCG) | Phase 3 | Assisted Reproductive Techniques |
| Enpatoran high dose | Phase 2 | Systemic Lupus Erythematosus |
| Enpatoran medium dose | Phase 2 | Systemic Lupus Erythematosus |
| Avelumab Injection | Phase 2 | Gestational Trophoblastic Neoplasias (GTN) |
| Rebif New Formulation + ibuprofen PRN | Phase 3 | Relapsing Multiple Sclerosis |
| Levo Praziquantel ODT | Phase 2 | Schistosomiasis |
| NKTR-255 | Phase 2 | Locally Advanced or Metastatic Urothelial Carcinoma |
| F0434 | Phase 3 | Diabetic Neuropathies |
| MSJ-0011 | Phase 3 | Anovulation |
| Chemotherapy + Immunotherapy Induction | Phase 2 | Muscle-invasive Bladder Cancer |
| Immunotherapy Maintenance | Phase 2 | Muscle-invasive Bladder Cancer |
| Recombinant Human Choriogonadotropin (r-hCG) | Phase 3 | Polycystic Ovarian Syndrome |
Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for MKKGY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
